David Lebowitz

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) reported second-quarter earnings and revenue Tuesday that blew past estimates, sending its shares solidly higher Wednesday. The Analysts Morgan Stanley analyst David Lebowitz maintained an Overweight rating on GW Pharma and increased the price...

Ionis Pharmaceuticals Inc (NASDAQ: IONS)'s partner Biogen Inc (NASDAQ: BIIB) reported fourth-quarter results Wednesday before the market open, revealing that sales of the spinal muscular atrophy treatment Spinraza came in at $470 million, missing the consensus estimate. Spinraza was...

By Sunday night, the U.S. Drug Enforcement Administration is expected to reclassify GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH)’s Epidiolex to allow medicinal use. This could open the therapy to a new and promising market. The Analyst  Morgan Stanley analyst David Lebowitz ...

A manufacturing-related hold on Sarepta Therapeutics Inc (NASDAQ: SRPT)’s Duchenne muscular dystrophy candidate catalyzed a recent sell-off. Morgan Stanley sees a buying opportunity in the otherwise-lauded program’s stumble.  The Analyst Analyst Matthew Harrison upgraded...

Avrobio Inc (NASDAQ: AVRO), a developer of gene therapy drugs targeting rare lysosomal storage disorders such as Fabry disease, Gaucher disease, Pompe disease and cystinosis, recently offered 5.25 million shares in an IPO. With the analyst quiet period expiring, the sell-side began initiating...

Unity Biotechnology Inc (NASDAQ: UBX) has fallen 22 percent since its May 3 initial public offering. Nonetheless, three sell-side firms initiated price targets implying significant upside Tuesday. The Rating Morgan Stanley analysts Matthew Harrison and David Lebowitz initiated coverage on Unity...

Commercial stage biopharma company Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)'s Linzess, which it markets along with Allergan plc (NYSE: AGN) in the U.S., is a major revenue earner for the company. In the first quarter, Ironwood received roughly 89 percent of its total revenues from...

Insmed Incorporated (NASDAQ: INSM), an orphan disease company developing treatment for nontuberculous mycobacterial lung disease, is likely to see upside from maintenance therapy and its sales opportunity in Japan, according to Morgan Stanley.  The Analyst Analyst Matthew Harrison initiated...

SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals.  It found further reason to celebrate Monday with the conversion of a new Street advocate. The Rating Morgan Stanley...

Celgene Corporation (NASDAQ: CELG) has gained about 15 percent from its mid-August lows. Against this backdrop of share price appreciation, Morgan Stanley said in a note Thursday that the consensus expectations underappreciate the potential for generic Revlimid as early as April 2020 and the...

Analysts at Morgan Stanley conducted a tracking survey to gain a better understanding of Sarepta Therapeutics Inc (NASDAQ: SRPT)'s outlook for its Exondys 51 therapy. After coming away with encouraging data, the firm's David Lebowitz upgraded Sarepta's stock rating from Equal Weight to Overweight...

Morgan Stanley in a research note released Monday noted that the Data Monitoring Committee has recommended Alnylam Pharmaceuticals, Inc.(NASDAQ: ALNY) continue with the trail without modification, following examination of safety data from the Phase III hATTR-PN trial. That said, the firm believes...

Raptor Pharmaceutical Corp. (NASDAQ: RPTP), a biopharmaceutical company with a focus on developing and commercializing transformative treatments for people affected by rare and debilitating diseases, announced Thursday evening that it has entered into a definitive agreement with Tripex...